Free Trial
→ Trump’s treachery (From Porter & Company) (Ad)
NYSEAMERICAN:AZTR

Azitra 11/14/2023 Earnings Report

Azitra logo
$0.28 -0.01 (-3.45%)
Closing price 05/28/2025 04:10 PM Eastern
Extended Trading
$0.27 -0.01 (-2.14%)
As of 04:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings History

Azitra EPS Results

Actual EPS
-$4.80
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Azitra Revenue Results

Actual Revenue
$0.31 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azitra Announcement Details

Quarter
Date
11/14/2023
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Azitra's next earnings date is estimated for Monday, August 11, 2025, based on past reporting schedules.

Conference Call Resources

Azitra Earnings Headlines

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash
May 28 at 8:33 AM | prnewswire.com
FY2025 EPS Estimates for Azitra Lifted by Zacks Small Cap
May 24, 2025 | americanbankingnews.com
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon bring Elon Musk's DOGE operation to its final, dramatic conclusion - with huge consequences for millions of investors. So if you have any money in the market... you're almost out of time to prepare. This plan has already been put in place... and can operate even if Elon's long gone from Washington.
May 29, 2025 | Altimetry (Ad)
Q2 Earnings Forecast for Azitra Issued By Zacks Small Cap
May 24, 2025 | americanbankingnews.com
AZTR: ATR-04 Trial to Dose 1st Patient Mid-2025
May 21, 2025 | finance.yahoo.com
Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash
May 14, 2025 | prnewswire.com
See More Azitra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email.

About Azitra

Azitra (NYSEAMERICAN:AZTR), an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

View Azitra Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles